Aspen Neuroscience and Bambusa raise $310M combined in IPOs

Aspen Neuroscience, a biotech focused on cell therapy for Parkinson's disease, announced it will raise about $141 million through its initial public offering scheduled for Friday.

Bambusa, a startup developing innovative immunology and infectious disease solutions founded by former BioNTech leaders, is set to collect roughly $169 million in its IPO on the same day.

The two offerings add to a recent wave of biotech companies accessing public markets, highlighting strong investor interest in novel therapies and platform technologies.

Both companies will list on U.S. exchanges, expanding the pool of publicly traded pharmaceutical innovators.